PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro (Q21195212)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro	scientific article

Statements

scholarly article

1 reference

13 November 2016

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro (English)

1 reference

13 November 2016

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Charles Ginther

7

object named as

Charles Ginther

author given names

Charles

author last names

Ginther

1 reference

Dimensions Publication ID

17 August 2022

2

object named as

Judy Dering

author given names

Judy

author last names

Dering

1 reference

Dimensions Publication ID

17 August 2022

3

object named as

Dylan Conklin

author given names

Dylan

author last names

Conklin

1 reference

Dimensions Publication ID

17 August 2022

object named as

Ondrej Kalous

4

author given names

Ondrej

author last names

Kalous

1 reference

Dimensions Publication ID

17 August 2022

author name string

Richard S Finn

1

author given names

Richard S

author last names

Finn

1 reference

Dimensions Publication ID

17 August 2022

David J Cohen

5

author given names

David J

author last names

Cohen

1 reference

Dimensions Publication ID

17 August 2022

Amrita J Desai

6

author given names

Amrita J

author last names

Desai

1 reference

Dimensions Publication ID

17 August 2022

Mohammad Atefi

8

author given names

Mohammad

author last names

Atefi

1 reference

Dimensions Publication ID

17 August 2022

Isan Chen

9

author given names

Isan

author last names

Chen

1 reference

Dimensions Publication ID

17 August 2022

Camilla Fowst

10

author given names

Camilla

author last names

Fowst

1 reference

Dimensions Publication ID

17 August 2022

Gerret Los

11

author given names

Gerret

author last names

Los

1 reference

Dimensions Publication ID

17 August 2022

Dennis J Slamon

12

author given names

Dennis J

author last names

Slamon

1 reference

Dimensions Publication ID

17 August 2022

language of work or name

0 references

publication date

2009

0 references

Breast Cancer Research

0 references

11

0 references

R77

0 references

5

0 references

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

19 March 2017

The Hallmarks of Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

19 March 2017

Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

19 March 2017

Cyclin D1 in breast cancer pathogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

19 March 2017

Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

19 March 2017

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

19 March 2017

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

19 March 2017

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

19 March 2017

Molecular portraits of human breast tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

6 April 2017

Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

19 March 2017

Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

19 March 2017

CDK-independent activation of estrogen receptor by cyclin D1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

19 March 2017

Requirement for CDK4 kinase function in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

19 March 2017

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

7 April 2017

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

7 April 2017

Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

12 September 2017

RB in breast cancer: at the crossroads of tumorigenesis and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

12 September 2017

Cell cycle control in breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

12 September 2017

Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

12 September 2017

Cell-cycle targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

12 September 2017

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

12 September 2017

Specific protection against breast cancers by cyclin D1 ablation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

12 September 2017

Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

12 September 2017

Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

27 September 2017

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

27 September 2017

Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

27 September 2017

Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

27 September 2017

Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

27 September 2017

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

27 September 2017

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

27 September 2017

N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

27 September 2017

Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

27 September 2017

Rb depletion results in deregulation of E-cadherin and induction of cellular phenotypic changes that are characteristic of the epithelial-to-mesenchymal transition.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

29 November 2018

Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

29 November 2018

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

29 November 2018

Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

29 November 2018

Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

29 November 2018

Cyclin D1 and prognosis in human breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

29 November 2018

Determination of the prognostic value of cyclin D1 overexpression in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2790859

29 November 2018

In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19874578

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19874578

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclins and breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19874578

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression and amplification of cyclin genes in human breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19874578

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining

1 reference

https://pubmed.ncbi.nlm.nih.gov/19874578

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclin D1 protein expression and function in human breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19874578

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene

1 reference

https://pubmed.ncbi.nlm.nih.gov/19874578

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Control of the cell cycle and apoptosis

1 reference

https://api.crossref.org/works/10.1186%2FBCR2419

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1186/BCR2419

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Dimensions Publication ID

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Springer Nature article ID

10.1186/bcr2419

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q21195212&oldid=1832488503"